Assessing infectious diseases in a "One health" context.
Conditions
Interventions
Group 1: The study design is a cross-sectional feasibility study without randomisation, blinding or placebo control. It is based on a population-based cohort and initially comprises a uniform survey i
animal testing can occur later, a flexible appointment will be made with each household):
- Household questionnaire (right after enrollment)
- Domestic animals (sheep, goats, cows): Swabs (oral, nasop
Sponsors
Helmholtz Institut für One Health (HIOH)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Individuals residing in one of the nine selected villages around the Taï National Park and have lived in the area for at least six months - Individuals of all age groups and genders; this includes healthy individuals and those with existing conditions. - Both adults (=18 years old) and children (<18 years) are included, with special provisions for minors involving parental or guardian consent. - Individuals with pre-existing conditions such as mental disorders and who are able to give consent are eligible for inclusion. - Pregnant women are included. - At the household level, participants are considered part of a household if they are living in the same compound, sharing facilities such as toilet and kitchen utensils, make meals together.
Exclusion criteria
Exclusion criteria: - Individuals who decline participation, fail to give informed consent, or are unavailable for the appointment are excluded, maintaining voluntary participation principles. - Guests, migrants, and those with unclear or uncertain residence status are not eligible to participate, to ensure clear and stable cohort tracking. - Individuals unable to give their consent and no responsible guardian or carer who could give consent on their behalf.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Number of participants recruited, broken down by region and age group. - Proportion of all study procedures completed in full, including physical examinations (e.g. body temperature, blood pressure, lung function, anthropometry) and biological sampling. - Completeness and quality of the questionnaire data collected. Timeframe of the study will be the following: October – December 2025: Preparation of documents for the ethics committee; awareness-raising among the community and local authorities; information distribution about the study in local communities; pre-testing and validation of data collection instruments. January 2026: Training of local staff; logistical preparations in villages; preparation of the field laboratory, recruitment of participants February – May 2026: One Health Cohort: physical examinations for candidates, collection of biological samples, administration of questionnaires. May 2026 – May 2027: Analysation of the samples and interpretation of the data. Endpoints will be checked after the end of data collection from May 2026 onwards. The completeness of the questionnaires, etc. can already be evaluated on an ongoing basis during the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Infection rates and immunity levels for relevant zoonotic infections. - Influence of household and non-household contact behaviour on infection rates and dynamics. - Evaluation of participants' general health status based on clinical, biochemical and functional measurements taken on site. - Prevalence and distribution of antimicrobial resistance in environmental, animal and human samples in the study region. - Analysis of the human microbiome and its relationship to environmental factors. - Analysis of climate-related environmental stressors (temperature, humidity, air exposure) and their influence on the barrier function of the respiratory mucosa. - Prevalence of chronic kidney disease and possible links to infectious diseases and environmental factors. - Creation of immunological reference profiles in healthy study participants from the Tai cohort through analysis of peripheral blood mononuclear cells (PBMCs). | — |
Countries
Côte d’Ivoire
Contacts
Public ContactFabian Leendertz
HIOH
Outcome results
None listed